CORCEPT THERAPEUTICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $761.4 | $675.0 | $482.4 | $401.9 | $366.0 |
| Operating income | $44.8 | $137.0 | $107.3 | $112.6 | $124.5 |
| Net income | $99.7 | $141.2 | $106.1 | $101.4 | $112.5 |
| Cash Flow Statement | |||||
| Free cash flow | $141.8 | $196.1 | $126.5 | $119.9 | $167.4 |
| Share repurchases | $172.9 | $15.7 | $0.0 | $0.0 | — |
Shares outstanding 108.1M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of September 25, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 15, 2026
Theme Survey
Corcept Flags Direct Revenue Hit as IRA Pricing Rules Widen
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back